A company fighting cancer, a device to stop sleep disorder and a project to make local anaesthetics safer have been handed major cash boosts. The Medtech Accelerator programme, which is run in partnership with the New Anglia Local Enterprise Partnership (LEP), awarded grants of £80,000 to £125,000 to four projects across East Anglia including two […]
Medical device company Ablatus Therapeutics Ltd, has been founded to develop and commercialise a novel tissue ablation technology to treat the most challenging and often inoperable, solid cancer tumours. Spun-out of Norfolk & Norwich University Hospitals NHS Foundation Trust (NNUH) with support from Health Enterprise East (HEE), investment totalling £500K comes from Anglia Capital Group, […]
UK government-created and EU-backed institutions support Ablatus Therapeutics in its $648,000 round to commercialise a potential treatment for solid cancer tumours. Ablatus Therapeutics, a UK-based medical device spinout from Norfold and Norwich University Hospitals NHS Foundation Trust, has raised £500,000 ($648,000) from a consortium including the Low Carbon Innovation Fund. The Low Carbon Innovation Fund, […]
Ablatus Therapeutics Ltd, a medical device company, has been founded to develop and commercialise a novel tissue ablation technology to treat the most challenging and often inoperable, solid cancer tumours. Spin out company raises £500k seed funding to progress development towards CE-marking and human studies The start-up company has spun-out of Norfolk & Norwich University […]
A Future50 firm targeting a breakthrough in cancer treatment has moved a step closer to developing life-saving treatment after completing a half-million pound funding round. Ablatus Therapeutics is the first commercial spin-out from the Norfolk and Norwich University Hospital, which has a stake in the company, and builds on research which identified a more efficient […]
Our technology, Bimodal Electric Tissue Ablation (BETA) is next-generation radiofrequency ablation offering larger, more effective ablations with potentially fewer adverse events and at lower cost than RFA.